title: Olanzapine long-acting injection: insights from an early case series in the UK.
abstract: OBJECTIVE
  Olanzapine long-acting injection depot (OLAI) has been licensed in the UK since 2008. As a result of the recognition during clinical trials that in 0.07% of injections there may be inadvertent intravenous administration leading to post-injection delirium/sedation syndrome (PDSS), the licence mandates a 3 h observation after each injection and accompaniment of the patient to their final destination. The administration of OLAI may thus necessitate organization of local service provisions. We report on how a single healthcare facility in Northern Ireland has treated three initial patients and present a brief case series on these patients and their clinical outcomes.
  
  
  METHODS
  In the first three patients with schizophrenia to receive OLAI, the clinical notes were retrospectively examined to provide clinical data.
  
  
  RESULTS
  All three patients had acceptable clinical outcomes showing sustained clinical improvement and have continued on OLAI for over 1 year. Observation has been undertaken within an existing daycare unit staffed by nursing staff and occupational therapists for 3 h after each injection. No issues have emerged from the use of this service that has also provided educational and psycho-educational programmes for the patients. No cases of post-injection delirium/sedation syndrome were reported. There have been no additional cost implications.
  
  
  CONCLUSIONS
  In patients for whom OLAI may be clinically indicated, the utilization of an existing service to provide the 3 h of observation after each injection may represent a solution with a cost-neutral outcome.
authors: Gransha Hospital, Derry, UK.
authors: Deirdre
authors: D
authors: McGlennon
authors: Chris J
authors: CJ
authors: Bushe
keywords: depot antipsychotic; healthcare facility; olanzapine; olanzapine long-acting injection; postinjection delirium sedation syndrome; schizophrenia
references: BMC Psychiatry. 2010 Jun 10;10:43
references: 20537128
references: BMC Psychiatry. 2010 Jun 10;10:45
references: 20537130
references: J Clin Psychiatry. 2009;70 Suppl 4:1-46; quiz 47-8
references: 19686636
references: J Clin Psychopharmacol. 2011 Aug;31(4):411-7
references: 21694620
references: Ann Intern Med. 2007 Aug 21;147(4):283-4
references: 17709768
references: Am J Psychiatry. 2011 Jun;168(6):603-9
references: 21362741
references: J Psychopharmacol. 2010 Nov;24(4 Suppl):17-25
references: 20923917
references: Sex Transm Dis. 1978 Jan-Mar;5(1):4-9
references: 417409
references: Am J Psychiatry. 2010 Feb;167(2):181-9
references: 20008947
references: Curr Drug Saf. 2011 Feb 1;6(1):43-5
references: 21047303